SCHEMBL24253932

SCHEMBL24253932

O=C1CCCC2(CCN(c3cn(-c4ccc(F)cc4)nn3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
CYP11B2 P19099 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
RXRA P19793 2/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2B Q13224 2/20 0.31
RAD51 Q06609 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
LTC4S Q16873 1/20 0.31
IDO1 P14902 1/20 0.31
TDO2 P48775 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
MMP13 P45452 1/20 0.31
GRM5 P41594 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424672 1.00 KCNH2 (0.35) KCNH2SMN1; SMN2CYP11B2NPC1RAB9A
SCHEMBL30424099 0.88 KMT2A (0.33) KCNH2CYP11B2MAPTRAD51HCRTR1
SCHEMBL24253578 0.88 KMT2A (0.33) KCNH2CYP11B2MAPTRAD51HCRTR1
SCHEMBL30424476 0.81 HCRTR1 (0.33) KCNH2SMN1; SMN2CYP11B2ALDH1A1MAPT
SCHEMBL24253724 0.81 HCRTR1 (0.33) KCNH2SMN1; SMN2CYP11B2ALDH1A1MAPT
SCHEMBL30424244 0.81 CYP11B2 (0.35) CYP11B2RAD51MMP13
SCHEMBL24253617 0.81 CYP11B2 (0.35) CYP11B2RAD51MMP13
SCHEMBL30494533 0.77 DPP4 (0.36) KCNH2CYP11B2RAD51HCRTR1HCRTR2
SCHEMBL24253536 0.77 DPP4 (0.36) KCNH2CYP11B2RAD51HCRTR1HCRTR2
SCHEMBL24253923 0.76 RAD51 (0.33) KCNH2CYP11B2RAD51HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 KCNH2 282/4885SMN1; SMN2 2877/4885CYP11B2 22/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 KCNH2 282/4885SMN1; SMN2 2877/4885CYP11B2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.